The CAR T-cell therapy is now approved for some patients with relapsed/refractory mantle cell lymphoma. The U.S. Food and Drug Administration (FDA) has approved lisocabtagene maraleucel (Breyanzi) for the treatment of adult patients with...
Aspirin appears to activate an immune response against colorectal cancer in the early stages of the disease.
The FDA approved the RET inhibitor selpercatinib for children with thyroid cancer and other solid tumors harboring various RET alterations. The U.S. Food and Drug Administration (FDA) has granted accelerated approval to selpercatinib (Retevmo)...
New immunotherapy approved for small cell lung cancer, and researchers investigate using urine tests to detect cancer.
Less frequent HPV tests detect precancerous lesions of the cervix just as well as more frequent Pap smears, which could help achieve The goal of eliminating the cancer. When it comes to detecting precancerous...
Disparities in cancer outcomes shrink but persist, and FDA approval increases access to HPV screening.
Tarlatamab-dlle is the first bispecific T-cell engager approved to treat a solid tumor. The U.S. Food and Drug Administration (FDA) has granted accelerated approval to tarlatamab-dlle (Imdelltra) to treat patients with extensive-stage small cell lung...
The CAR T-cell therapy received accelerated approval to treat advanced cases of pretreated follicular lymphoma. The U.S. Food and Drug Administration (FDA) has granted accelerated approval to lisocabtagene maraleucel (Breyanzi) for the treatment of...
New research fuels progress in cancer survival, prevention and side effect management.
People may be able to wait longer between colonoscopies, and a trial evaluates a less invasive option for treating prostate cancer.
AACR Fellow Lewis C. Cantley, PhD, leads a national effort targeting triple-negative breast cancer and ovarian cancer with a novel drug combination.
Learn MoreYour donation to the American Association for Cancer Research helps our more than 58,000 members worldwide drive progress against cancer.
Donate Now